Frank R. Lichtenberg is Cain Brothers & Company Professor of Healthcare Management in the Faculty of Business Economics at the Columbia University Graduate School of Business; a Research Associate of the National Bureau of Economic Research; and a member of the CESifo Research Network. He received a BA with Honors in History from the University of Chicago and an MA and PhD in Economics from the University of Pennsylvania.

Professor Lichtenberg previously taught at Harvard University, the University of Pennsylvania, and Ecole Polytechnique. He has served as an expert for the Federal Trade Commission, the U.S. Department. of Justice, and state Attorneys General, and has testified before Congress. He has worked for several U.S. government agencies, including the Department of Justice, the Congressional Budget Office, and the Census Bureau, and been a visiting scholar at the Wissenschaftszentrum Berlin, the University of Munich, and elsewhere.

Some of Professor Lichtenberg’s research has examined how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. He has performed studies of the impact of pharmaceutical innovation on longevity, the effect of computers on productivity in business and government organisations, and the consequences of takeovers and leveraged buyouts for efficiency and employment. His articles have been published in numerous scholarly journals and in the popular press. His book Corporate Takeovers and Productivity has been published by MIT Press.

Professor Lichtenberg was awarded the 1998 Schumpeter Prize for his paper, Pharmaceutical Innovation as a Process of Creative Destruction; the 2003 Milken Institute Award for Distinguished Economic Research for the paper, Pharmaceutical Knowledge-Capital Accumulation and Longevity; and Research!America’s 2010 Garfield Economic Impact Award for the paper, The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004.

He has been awarded research fellowships, grants, and contracts by the National Science Foundation, the World Health Organization, the National Institute of Standards and Technology, Merck and Co., the Fulbright Commission, the Brookings Institution, the Alfred P. Sloan Foundation, The German Marshall Fund, the American Enterprise Institute, and other organisations. He has served as a consultant to private organisations and government agencies, including the Securities Industry Association, Pfizer, Inc., the Community Preservation Corporation, the RAND Corporation, the New York City Water Board, Touche Ross and Co., The Walt Disney Company, McGraw-Hill, and the National Pharmaceutical Council.

Paul Cross is the founder of Daily Dispatch, the publisher of PharmaDispatch, BiotechDispatch and HealthDispatch, online journals focused on providing news and analysis concerning the Australian pharmaceutical, biotechnology and private health sectors. He has over 15 years’ experience in health care, having served in senior roles in government and the private sector.

Anne-Maree Englund is passionate about the potential of innovative technologies to improve health outcomes. She has over 20 years’ experience in the biopharmaceutical and medical technology industries. An engineer by trade, Anne-Maree started her career at the medical device innovator Cochlear, with roles in manufacturing and quality management, including four years in Switzerland and Belgium.

She has been General Manager of Operations at health IT startup Humanetix, seeing the company through a successful clinical trial of their unique software. After completing a master’s degree in public policy, Anne-Maree worked as Policy Manager at pharmaceutical company MSD. She is currently Head of Strategic Policy Implementation at Medicines Australia, a role which perfectly combines her interests in medical innovation and health policy.

With a passion for the importance of the patient voice in federal policy, Deidre has held several senior management and executive roles within the public health sector, as well as gaining invaluable experience in the not-for-profit space as former CEO of Multiple Sclerosis Australia.

In addition to her work at the APAA, Deidre is also the board chair of St Kilda Mums, a Victorian based charity focused on rehoming pre-loved nursery goods to provide babies with a safe start in life.

James McDonnell is a senior biopharmaceutical executive with over 30 years’ experience including the invaluable knowledge of establishing two original Australian affiliates with full profit and loss responsibility. A proven track record of success which can be attributed to building exceptional partnerships, creating a patient-centered focus, developing positive cultures whilst maintaining a high level of determination. His drive and resilience have enabled him to be agile to the needs of the businesses and continuing to drive a high performance culture with a clear purpose and vision.

James is a pharmacist and holds a GAICD from the Australian Institute of Company Directors. James has been an employee with CSL Vifor for 13 years in Australia and has held the role of General Manager throughout that period. James established the affiliate as employee number 1 and guided its growth in employees and a network of partners. James is currently a member of the Board of Medicines Australia.